clexane injection 4000 iu (40mg)0.4 ml
sanofi-aventis singapore pte. ltd. - enoxaparin sodium - injection - 4000 anti-xa iu (40mg)/0.4 ml - enoxaparin sodium 4000 iu (40mg)/0.4 ml
clexane injection 6000 iu (60mg)0.6 ml
sanofi-aventis singapore pte. ltd. - enoxaparin sodium - injection - 6000 anti-xa iu (60mg)/0.6 ml - enoxaparin sodium 6000 iu (60mg)/0.6 ml
clexane injection 8000 iu (80mg)0.8 ml
sanofi-aventis singapore pte. ltd. - enoxaparin sodium - injection - 8000 anti-xa iu (80mg)/0.8ml - enoxaparin sodium 8000 iu (80mg)/0.8ml
clexane 10,000 iu (100 mg)/1 ml solution for injection in pre-filled syringes
pco manufacturing ltd. - enoxaparin sodium - solution for injection in pre-filled syringe - 10000 international unit(s) - enoxaparin
clexane 4,000 iu (40 mg) /0.4 ml solution for injection in pre-filled syringes
pco manufacturing ltd. - enoxaparin sodium - solution for injection in pre-filled syringe - 40 milligram(s) - enoxaparin
clexane 6,000 iu (60 mg) /0.6 ml solution for injection in pre-filled syringes
pco manufacturing ltd. - enoxaparin sodium - solution for injection in pre-filled syringe - 60 milligram(s) - enoxaparin
clexane 8,000 iu (80 mg) /0.8 ml solution for injection in pre-filled syringes
pco manufacturing ltd. - enoxaparin sodium - solution for injection in pre-filled syringe - 80 milligram(s) - enoxaparin
clexane forte 12,000 iu (120 mg) / 0.8 ml solution for injection in pre-filled syringes
pco manufacturing ltd. - enoxaparin sodium - solution for injection in pre-filled syringe - 120 milligram(s) - enoxaparin
clexane 2,000 iu (20mg) /0.2 ml solution for injection in pre-filled syringes
pco manufacturing ltd. - enoxaparin sodium - solution for injection in pre-filled syringe - enoxaparin
clexane forte enoxaparin sodium 120mg/0.8ml injection syringe with automatic safety lock system
sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 120 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).